Key facts
- FLAG Therapeutics’s last known valuation is $40.0M (Jul 2019).
- It has raised $4.0M across 1 recorded rounds; the latest was Seed Round ($1.3M) in Mar 2016.
- Notable investors include Springhood, U.S. Department of Health and Human Services.
- FLAG Therapeutics has filed 4 Form Ds with the SEC since 2016, most recently Jul 2019 ($73K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for FLAG Therapeutics
Funding rounds
1 roundsAbout FLAG Therapeutics
Operator of an oncology company intended to develop a dual-acting small molecule for the treatment of Glioblastoma. The company focuses on developing new small-molecule therapeutics for difficult-to-treat cancer and its therapies are based on two investigational product platforms that are Anti-angiogenic, Anti-tubulin and the Folate-target Anti-cancer (FTAC) that includes multiple water-soluble small molecule compounds, enabling doctors to treat multiple cancer types, including brain, lung, ovarian and pancreatic.
- Sector
- Healthcare
- HQ
- Raleigh, NC, United States
- Founded
- 2013
- Employees
- 5
- Website
- flagtherapeutics.com/
- Ownership
- Privately Held (backing)
FLAG Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FLAG Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FLAG Therapeutics in its N-PORT filings yet. We sweep new filings monthly.